Skip to main content

Table 1 Baseline characteristics

From: Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection

 

All patients

Telaprevir

Boceprevir

(N = 102)

(N = 65)

(N = 37)

 

N (%); median (range)

N (%); median (range)

N (%); median (range)

Male sex

63 (62%)

43 (66%)

20 (54%)

Exclusion criteria for appropriate phase III trials

65 (64%)

42 (65%)

23 (62%)

Treatment naïve

47 (46%)

23 (35%)

24 (65%)

Treatment experienced

55 (54%)

42 (65%)

13 (35%)

Relapse

25 (25%)

18 (28%)

7 (19%)

Null/partial response

15 (15%)

13 (20%)

2 (5%)

Breakthrough

6 (6%)

5 (8%)

1 (3%)

Discontinuation §

5 (5%)

3 (5%)

2 (5%)

Unknown outcome

4 (4%)

3 (5%)

1 (3%)

DAA experienced

10 (10%)

9 (14%)

1 (3%)

RVR

38 (37%)

21 (32%)

17 (46%)

Genotype

   

Genotype 1a

39 (38%)

20 (31%)

19 (51%)

Genotype 1b

53 (52%)

37 (57%)

16 (43%)

No subtype provided

9 (9%)

7 (11%)

2 (5%)

Unknown

1 (1%)

1 (2%)

0

IL28B (N = 70)

   

C/C

16 (24%)

10 (20%)

6 (29%)

C/T

42 (60%)

32 (65%)

10 (48%)

T/T

12 (17%)

7 (14%)

5 (24%)

Stage of fibrosis (N = 92)

   

No or mild fibrosis (F0-F2)

51 (55%)

32 (49%)

19 (59%)

Bridging fibrosis (F3)

12 (13%)

6 (10%)

6 (19%)

Liver cirrhosis

29 (32%)

22 (37%)

7 (22%)

Hemoglobin [g/dl]

14.7 (10.3-18.8)

14.7 (11.1-18.8)

14.6 (10.3-17.6)

Leukocytes [x10^9/l]

6.1 (2.7-13.1)

5.9 (2.7-13.1)

6.3 (3.9-12.4)

Platelets [x10^9/l]

188 (48–377)

180 (48–377)

203 (67–338)

ASAT [U/l]

50.5 (16–328)

52 (16–328)

44 (19–156)

ALAT [U/l]

75.5 (16–271)

87 (16–271)

72 (19–227)

γGT [U/l]

66.5 (25–1274)

67 (25–1274)

62 (25–217)

Bilirubin [mg/dl]

0.5 (0.2-2.2)

0.6 (0.3-2.2)

0.5 (0.2-1.4)

Albumin [g/l]

40 (25–50)

40 (25–47)

39 (30–50)

Prothrombin time [INR]

1.00 (0.90-3.29)

1.02 (0.90-3.29)

1.00 (0.92-2.33)

Creatinine [mg/dl]

0.8 (0.5-5.8)

0.8 (0.5-1.1)

0.8 (0.5-5.8)

Viral load undetectable at

   

EOT

82 (80%)

51 (78%)

31 (84%)

SVR12

62 (61%)

40 (62%)

22 (59%)

  1. [N = number; DAA = direct acting antivirals; RVR = rapid virological response; IL28B = interleukin-28B polymorphism; EOT = end of treatment; SVR12 = sustained virological response 12 weeks after last ribavirin dose; § = cessation of prior therapy due to side-effects].